Head-to-head
Hims & Hers vs HealthRX
Compared on both medications across the eight dimensions this database records. They differ on 7 of those eight. HealthRX is cheaper on all-in tirzepatide at 10 mg/week, though on a flat-versus-tiered matchup the cheaper program can change further up the dose ladder.
The short answer
Hims & Hers is $697 a month all-in for tirzepatide; HealthRX is $209. Over twelve months that is $8,364 against $2,148. Value Scores are 27.5 and 82.1 out of 100.
Tirzepatide
Plan pages: Hims & Hers plans · HealthRX plans
At 10 mg/week, Hims & Hers is $697 a month all-in and HealthRX is $209 — $488 apart, or $5,856 across a year. Over twelve months the totals are $8,364 (billed monthly) and $2,148 (prepaid term).
Hims & Hers charges a flat $548 per month for tirzepatide at every dose from 2.5 to 15 mg per week, so titrating upward does not change what you pay. The company publishes no price at 5, 7.5, 12.5, 15 mg, so those doses are left blank rather than estimated.
HealthRX charges a flat $209 per month for tirzepatide at every dose from 2.5 to 15 mg per week, so titrating upward does not change what you pay.
| Dose | Hims & Hers | Rank | HealthRX | Rank | Cheaper |
|---|---|---|---|---|---|
| 2.5 mg | $548 | 30/31 | $209 | 11/31 | HealthRX by $339 |
| 5 mg | — | — | $209 | 5/17 | only HealthRX publishes |
| 7.5 mg | — | — | $209 | 5/17 | only HealthRX publishes |
| 10 mg | $548 | 25/27 | $209 | 5/27 | HealthRX by $339 |
| 12.5 mg | — | — | $209 | 5/17 | only HealthRX publishes |
| 15 mg | — | — | $209 | 5/17 | only HealthRX publishes |
HealthRX is cheaper at every dose where both publish a price, so the lead does not change as you titrate.
Across the 27 programs this database can rank on tirzepatide, Hims & Hers sits 25 of 27 on all-in monthly cost and HealthRX sits 5. There are 19 other programs priced between them. The field median is $339 and the floor is $169, so HealthRX is below the median and the other is above it. Hims & Hers is $528 above the cheapest tirzepatide program on record. HealthRX is $40 above the cheapest tirzepatide program on record.
LillyDirect (Zepbound), the lowest FDA-approved tirzepatide channel here, is $449 a month — Hims & Hers undercuts it by $-248, HealthRX by $240. Compounded products are not FDA approved; insurance can reverse that comparison.
| Plan term | Hims & Hers | HealthRX | Cheaper |
|---|---|---|---|
| Month to month | $548 | — | only Hims & Hers publishes this term |
| 3-month term | — | $209 | only HealthRX publishes this term |
| 12-month term | — | $179 | only HealthRX publishes this term |
| Settled dose | Hims & Hers | HealthRX | Difference |
|---|---|---|---|
| 2.5 mg | $8,364 | $2,508 | $5,856 apart |
| 5 mg | — | $2,508 | one side unpriced |
| 7.5 mg | — | $2,508 | one side unpriced |
| 10 mg | $8,364 | $2,508 | $5,856 apart |
| 12.5 mg | — | $2,508 | one side unpriced |
| 15 mg | — | $2,508 | one side unpriced |
Hims & Hers publishes no rate for 3-month term, 6-month term, 12-month term; HealthRX publishes none for month to month, 6-month term. An unpublished term is not necessarily unavailable — it is unpriced in public, which you can only resolve by asking.
A titration year is not twelve months at the maintenance price. Stepping up roughly four weeks per dose before settling at 10 mg/week, the first twelve months work out to $8,364 on Hims & Hers and $2,508 on HealthRX. The ramp is cheaper than the settled rate on whichever program prices by dose, which is why a first-year quote and a steady-state quote are not the same number.
That calculation is partial: Hims & Hers publishes no price at 2 of the 6 doses, so the maintenance rate stands in for the missing steps rather than a number the company has stated.
Value Scores are 27.5 for Hims & Hers and 82.1 for HealthRX, against a tirzepatide category floor of $169. HealthRX leads by 54.6 points, driven mostly by price.
| Program | Price /70 | Evidence /15 | Dose /10 | Membership /5 | Total /100 |
|---|---|---|---|---|---|
| Hims & Hers | 17.0 | 10.5 | 0 | 0 | 27.5 |
| HealthRX | 56.6 | 10.5 | 10 | 5 | 82.1 |
Semaglutide
Plan pages: Hims & Hers plans · HealthRX plans
At 2.4 mg/week, Hims & Hers is $602 a month all-in and HealthRX is $133 — $469 apart, or $5,628 across a year. Over twelve months the totals are $7,224 (billed monthly) and $1,188 (prepaid term).
Hims & Hers charges a flat $453 per month for semaglutide at every dose from 0.25 to 2.4 mg per week, so titrating upward does not change what you pay. The company publishes no price at 0.5, 1, 1.7 mg, so those doses are left blank rather than estimated.
HealthRX charges a flat $133 per month for semaglutide at every dose from 0.25 to 2.4 mg per week, so titrating upward does not change what you pay.
HealthRX is cheaper at every dose where both publish a price, so the lead does not change as you titrate.
Value Scores are 25.5 for Hims & Hers and 93.4 for HealthRX, against a semaglutide category floor of $129. HealthRX leads by 67.9 points, driven mostly by price.
Where the two programs differ
All-in monthly
HealthRX is cheaper month to month — $209 against $697, a gap of $488 every month, or $5,856 across a year if both rates hold.
Cancellation terms
Cancellation differs: Hims & Hers states Cancel anytime, while HealthRX states Per provider terms; confirm at enrollment. Read this next to the twelve-month figures — a prepaid discount and a restrictive refund policy are the same decision.
Commitment
Hims & Hers asks for Membership month-to-month ($39 first month); HealthRX asks for 12-month or 3-month plans only; no month-to-month rate published. This is the dimension most likely to change which program is actually cheaper for you, because the lowest rates on both sides are usually attached to the longest terms.
Dose policy
HealthRX charges one price at every dose; Hims & Hers prices by dose. That difference usually matters more than the headline gap, because the tiered program's advertised figure describes the dose you start on, not the dose you settle at.
Membership fee
Hims & Hers charges a membership of $149 a month on top of the medication. That is already folded into the all-in figures above — it is broken out here because a membership is a recurring charge that continues even in a month you skip a shipment.
Shipping
Hims & Hers bills shipping separately at $5; the other includes it.
Twelve-month cost
Over twelve months the totals are $8,364 for Hims & Hers and $2,148 for HealthRX. HealthRX is lower by $6,216 — a figure worth checking against the cancellation terms below, because a prepaid year is only cheaper if you stay on it.
Evidence status
Both figures carry the same evidence status, reported: sourced from dated third-party reporting; first-party capture pending. Neither is stronger than the other on provenance.
What each record says
Hims & Hers Official site
After settling with Novo Nordisk on March 9, 2026 and exiting compounded semaglutide for new patients, Hims & Hers now runs a branded-only GLP-1 service: Wegovy injection $299/month, oral Wegovy $249/month, and Zepbound $399/month, on top of a $149/month membership ($39 first month) plus $5 shipping.
It names its compounding pharmacy — Brand fulfillment (Wegovy, oral Wegovy, Zepbound) + partner pharmacy, recorded as Brand channel — which can be checked against state board licensing and FDA inspection records before you order; commitment terms are Membership month-to-month ($39 first month); cancellation is Cancel anytime; availability is stated as 50 states.
Evidence: reported — sourced from dated third-party reporting; first-party capture pending, captured . Source — Post-settlement pricing reported May–Jun 2026 (Wegovy $299 / oral $249 / Zepbound $399 + $149 membership + $5 shipping); first-party checkout capture pending
Watch: The membership is the number that moves the math: a $299 Wegovy pen becomes ~$453/month all-in. Compare against going to NovoCare or LillyDirect directly.
HealthRX Official site
HealthRX offers flat per-dose compounded GLP-1 pricing on 12-month and 3-month commitment plans. Its $99/mo semaglutide and $179/mo tirzepatide on the twelve-month plan rank among the lowest annualized figures in the market. No month-to-month rate is published.
It does not publicly name its compounding pharmacy; the record shows healthrx.com (pharmacy partner not publicly named), so who actually makes the medication cannot be independently verified; commitment terms are 12-month or 3-month plans only; no month-to-month rate published; cancellation is Per provider terms; confirm at enrollment; availability is stated as Confirm availability at intake.
Evidence: reported — sourced from dated third-party reporting; first-party capture pending, captured . Source — rangeyourself.com, capture verified 2026-07-18 on healthrx.com
Watch: HealthRX publishes no month-to-month rate; the $99/mo sema and $179/mo tirz are 12-month plan rates. The lowest commitment available is the 3-month plan ($133 sema, $209 tirz). Reported status — RangeYourself verified 2026-07-18 on healthrx.com; our independent checkout is pending.
What neither record tells you
Hims & Hers does not publish
- no tirzepatide price at 5, 7.5, 12.5, 15 mg per week
- no published twelve-month tirzepatide rate
- no semaglutide price at 0.5, 1, 1.7 mg per week
- no published twelve-month semaglutide rate
HealthRX does not publish
- no named compounding pharmacy
- no state-by-state availability list — it says Confirm availability at intake
- no specific cancellation or refund terms
Ask Hims & Hers and HealthRX for each of those in writing before enrolling. A gap is not evidence of a problem; it does mean nothing can be checked against it.
What would change this answer
Evidence may be upgraded. Hims & Hers, HealthRX carry a price we have not captured at checkout. A capture would move the evidence term and could reorder these two without any price changing.
Prepaid terms move the annual figures. HealthRX publishes a twelve-month rate of $179 a month against $209 month-to-month. Read those next to the cancellation terms, not the monthly rate.
Which one suits which reader
On the lowest standing monthly rate for tirzepatide, HealthRX Official site wins this matchup. If you expect to titrate to the top of the ladder, healthrx's flat pricing is worth more than the headline gap suggests; if you want to be able to pause without still paying, healthrx carries no membership.
Both figures should be checked at the provider's own checkout before you pay. Hims & Hers's tirzepatide price is reported as of 2026-08-11; HealthRX's is reported as of 2026-07-18.
Questions
Is Hims & Hers or HealthRX cheaper for tirzepatide?
HealthRX is cheaper on all-in monthly cost at 10 mg/week: $209 against $697, a difference of $488 a month. All-in means the medication plus every mandatory recurring fee.
What is the twelve-month cost of Hims & Hers versus HealthRX?
Hims & Hers works out to $8,364 across twelve months and HealthRX to $2,148, on the plan terms each publishes.
Does Hims & Hers or HealthRX raise the price as the dose goes up?
Hims & Hers: yes, it prices by dose. HealthRX: no, it charges one flat rate at every dose. Where one program is flat and the other is tiered, the cheaper of the two can change as you titrate upward.
How many ways do Hims & Hers and HealthRX differ?
7 of the eight dimensions this site records: all-in monthly, twelve-month cost, dose policy, membership, shipping, commitment, cancellation terms and evidence status.
Which of Hims & Hers and HealthRX names its pharmacy?
Hims & Hers does — Brand fulfillment (Wegovy, oral Wegovy, Zepbound) + partner pharmacy. HealthRX does not, recording only healthrx.com (pharmacy partner not publicly named), so who makes its medication cannot be independently verified.
How well evidenced are the Hims & Hers and HealthRX prices?
Hims & Hers's tirzepatide figure is reported — sourced from dated third-party reporting; first-party capture pending — captured 2026-08-11. HealthRX's is reported, captured 2026-07-18. Evidence status is worth fifteen points in the Value Score, so it is priced in rather than mentioned as an aside.
Which is cheaper for semaglutide?
HealthRX, at $133 a month all-in against $602 at 2.4 mg/week. The two programs do not necessarily lead on both medications.
Official sources: Hims & Hers official site · HealthRX official site. Compounded tirzepatide and semaglutide are not FDA-approved products.